Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|October 31, 2019
Launching Medical Devices in the Japanese Market - How to navigate regulatory and reimbursement approval
Author(s)IQVIA
This webinar will provide an overview of the Japanese regulations and development in the Japanese market. Live: Thursday, Oct. 31, 2019 at 11am EDT On demand available after airing until Oct. 31, 2020 Register free
Register free:
Event Overview:
Approximately 10 years ago “Device Lag” was a major topic of discussion related to the Japanese regulatory environment. Currently, the Japanese government and the PMDA have improved their processes and “Device Lag” is no longer an issue. As a result, through good preparation it is now possible to launch medical devices in the Japanese market in a timely manner. You now have more control over how quickly your product is launched.
Japan has a universal health insurance system and the government determines reimbursement device and physician fees. Reimbursement will be based on the regulatory approval conditions; therefore, reimbursement strategy should be part of your overall business plan. Your goal should be receiving good reimbursement approval and a successful launch in the Japanese market and not simply regulatory approval.
This webinar will provide an overview of the Japanese regulations and development in the Japanese market.
Key Learning Objectives:
Overview of the Japanese:
Medical Device Market
Insurance System
Regulatory Environment
Speaker: Hiroshi Iwai, Regulatory Consultant, IQVIA Japan Group
Time and Date: Thursday, Oct. 31, 2019 at 11am EDT
On demand available after airing until Oct. 31, 2020
Sponsor: IQVIA
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5